Brazil's CADE Fines Firms over Three-decade Global Pharma Cartel

Brazil's CADE Fines Firms over Three-decade Global Pharma Cartel
Photo: Getty Images 05.11.2026 793

Brazil’s CADE has fined four pharmaceutical companies and held three individuals liable for participating in a global cartel that allegedly controlled the SNBB market for three decades.

A five-year probe resulted in the liability of pharma companies Alchem International, Alkaloids of India, Alkaloids of Australia and Vital Laboratories. Three individuals, Christopher Kenneth Joyce, Rajiv Bajaj and Stefan Bertram, were also held accountable.

José Levi Mello do Amaral Júnior, the lead councilor on the case, imposed more than 17.5 million reais in fines ($3.2 million) during a Wednesday session. His vote was endorsed by the other members of the Tribunal, including Councilors Camila Cabral Pires Alves and Carlos Jacques Vieira Gomes.

CADE’s investigative arm, the Superintendence, concluded that the group engaged several forms of anticompetitive conduct, such as coordination of production and sales volumes, sale price coordination, creation of artificial entry barriers, and territorial or customer protection.

The conduct allegedly continued for at least three decades, from 1989 to 2019, according to the Brazilian investigation. In-person meetings, email exchanges and informal agreements were some of the strategies employed.

“The companies involved actively participated in and benefited from a cartel that controlled the global SNBB market for years and had a substantial impact on Brazil,”

the Superintendence said, adding that the “most substantial evidence” concerns the period from 2007 to 2019.

CADE’s Superintendence said that the evidence left no doubt that the pharma cartel produced anticompetitive effects in Brazil, particularly impacting women who take Buscopan to treat abdominal pain.

“Through frequent in-person meetings, often held at industry trade fairs, they negotiated and agreed on global production volumes with the aim of avoiding oversupply and keeping prices high.”

During the investigation, companies and individuals entered into settlement agreements with CADE. Boehringer Ingelheim and Transo-Pharm, as well as executives Hellmuth Spönnemann, Philipp Alexander Titulski and Stephen Mitchard cooperated with the Brazilian competition authority, admitting to the antitrust infringement.

`Source: MLex

pharmaceutical markets  Brazil 

Share with friends

Related content